Plus: Ad Council launches a new maternal mental health campaign for untreated conditions, and FDA grants priority review for elinzanetant to treat VMS.
Tiny Health raised $33 million in a Series B round led by B Capital, bringing total funding to $46 million and funding its new $5 million Microbiome Research Program, providing new tools for clinicians in microbiome analysis. Concurrently, the Ad Council launched its "The Secret to Motherhood" campaign on October 1, 2026, targeting new and expecting mothers to prioritize mental health, while the FDA accepted a supplemental New Drug Application for elinzanetant, granting it priority review for VMS treatment in women receiving endocrine therapy. These developments offer new avenues for care delivery and regulatory consideration for healthcare providers. Five takes inside, plus a quick-hits roundup.
VIA Crunchbase News
Tiny Health raised $33 million in a Series B funding round led by B Capital, bringing its total funding to $46 million. The company's B2B arm, Powered by Tiny, grew fourfold last year, serving over 6,000 practitioners. Tiny Health, which initially focused on infant testing and now counts adults as its larger segment, plans to use the capital to expand work with healthcare providers and fund research. This investment highlights continued investor interest in microbiome health solutions for both infant and adult populations.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire Health
On October 1, 2026, the Ad Council launched its "The Secret to Motherhood" campaign. The campaign encourages new and expecting mothers to prioritize their mental health. This initiative offers an opportunity for maternal mental health solution providers to align with public awareness efforts.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire Health
On October 1, 2026, the Ad Council will launch 'El Secreto de la Maternidad', a new maternal mental health campaign. This campaign encourages new and pregnant mothers to prioritize their mental health. Approximately 3 out of 4 maternal mental health conditions currently go untreated. This initiative highlights the ongoing need for solutions in maternal mental health, presenting an opportunity for femtech operators and clinicians.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
The FDA accepted a supplemental New Drug Application (sNDA) for elinzanetant and granted it priority review. Elinzanetant treats vasomotor symptoms (VMS) in women receiving endocrine therapy for HR+ breast cancer. This regulatory action could lead to a new treatment option for a specific population of women.
Read the full story →
— The Luteal Editorial Team